A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults

This study is a single arm, open label, dose exploring clinical trial to evaluate the safety, efficacy, cellular metabolic dynamics, and pharmacodynamics of ct1190b cells in relapsed / refractory B-cell acute lymphoblastic leukemia.

Trial Details

NCT ID

NCT07470073

Phase

EARLY_PHASE1

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Status

RECRUITING

Cancer Type

Leukemia

Interventions

CT1190B cell injection

Locations (sample)

Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

voluntarily participate in clinical research; I fully understand and know this study and sign the informed consent form; ;
aged 12-75 years (inclusive);
relapsed / refractory B-ALL diagnosed by morphology, immunology or molecular science, and meeting one of the following conditions:
The patients who did not achieve complete remission by the standardized induction chemotherapy, or early relapse (\<12 months) after complete remis…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →